Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jamie I Fletcher

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Science Translational Medicine|February 1, 2019
Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastomaLaura D Gamble, Stefania Purgato, Jayne Murray, et al.
Cancer Research|July 31, 2023
High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk CancerChelsea Mayoh, Jie Mao, Jinhan Xie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2021
Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in NeuroblastomaLin Xiao, Klaartje Somers, Jayne Murray, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2026
Correction: Targeted Therapy of TERT-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination TherapyJingwei Chen, Christopher Nelson, Matthew Wong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 14, 2020
Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination TherapyJingwei Chen, Christopher Nelson, Matthew Wong, et al.
Cell Death & Disease|March 13, 2021
Preclinical small molecule WEHI-7326 overcomes drug resistance and elicits response in patient-derived xenograft models of human treatment-refractory tumorsChristoph Grohmann, Francesca Walker, Mark Devlin, et al.
Nature Communications|June 13, 2026
The PLK4 inhibitor RP-1664 demonstrates potent efficacy in neuroblastoma preclinical models through a dual mechanism of sensitivityIsabel Soria-Bretones, Matias Casás-Selves, Minu Samanta, et al.
Nature Communications|July 11, 2024
The transcriptional co-repressor Runx1t1 is essential for MYCN-driven neuroblastoma tumorigenesisJayne E Murray, Emanuele Valli, Giorgio Milazzo, et al.
EMBO Molecular Medicine|December 20, 2021
In vitro and in vivo drug screens of tumor cells identify novel therapies for high-risk child cancerLoretta M S Lau, Chelsea Mayoh, Jinhan Xie, et al.
Cancer Cell|March 31, 2023
Generation and multi-dimensional profiling of a childhood cancer cell line atlas defines new therapeutic opportunitiesClaire Xin Sun, Paul Daniel, Gabrielle Bradshaw, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Science Translational Medicine|February 1, 2019
Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastomaLaura D Gamble, Stefania Purgato, Jayne Murray, et al.
Cancer Research|July 31, 2023
High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk CancerChelsea Mayoh, Jie Mao, Jinhan Xie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2021
Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in NeuroblastomaLin Xiao, Klaartje Somers, Jayne Murray, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2026
Correction: Targeted Therapy of TERT-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination TherapyJingwei Chen, Christopher Nelson, Matthew Wong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 14, 2020
Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination TherapyJingwei Chen, Christopher Nelson, Matthew Wong, et al.
Cell Death & Disease|March 13, 2021
Preclinical small molecule WEHI-7326 overcomes drug resistance and elicits response in patient-derived xenograft models of human treatment-refractory tumorsChristoph Grohmann, Francesca Walker, Mark Devlin, et al.
Nature Communications|June 13, 2026
The PLK4 inhibitor RP-1664 demonstrates potent efficacy in neuroblastoma preclinical models through a dual mechanism of sensitivityIsabel Soria-Bretones, Matias Casás-Selves, Minu Samanta, et al.
Nature Communications|July 11, 2024
The transcriptional co-repressor Runx1t1 is essential for MYCN-driven neuroblastoma tumorigenesisJayne E Murray, Emanuele Valli, Giorgio Milazzo, et al.
EMBO Molecular Medicine|December 20, 2021
In vitro and in vivo drug screens of tumor cells identify novel therapies for high-risk child cancerLoretta M S Lau, Chelsea Mayoh, Jinhan Xie, et al.
Cancer Cell|March 31, 2023
Generation and multi-dimensional profiling of a childhood cancer cell line atlas defines new therapeutic opportunitiesClaire Xin Sun, Paul Daniel, Gabrielle Bradshaw, et al.
Pageof 6